Faeth Therapeutics is a clinical-stage biotech firm developing cancer treatments, including PIKTOR, an experimental inhibitor of the PI3K/AKT/mTOR pathway being tested for endometrial and breast cancer, and Solnerstotug, a monoclonal antibody in early human trials targeting the VISTA immune checkpoint for solid tumors. The company's development portfolio also includes additional monoclonal antibodies and a bispecific antibody candidate in earlier-stage research. Based in Rockville, Maryland, Faeth was formerly known as Sensei Biotherapeutics before its name change in 2026.
1Y: 18.69 (+103.8%) · range 7.89–40.05
entry readiness 87 · STRONG SETUP · exit proximity 0
Value area 22.70–37.75 · 91% of 120d volume overhead · heavy supply
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +18.85% | +57.77% | mature |
| 40d | +47.64% | +57.77% | mature |